Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations
Pietro Castellan,1 Michele Marchioni,2 Roberto Castellucci,1 Piergustavo De Francesco,2 Romina Iantorno,1 Luigi Schips,1,2 Luca Cindolo1 1Department of Urology, ASL02 Abruzzo, Chieti, Italy; 2Department of Urology, University “G. d’Annunzio”, Chieti, Italy Abstract: In...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2018-12-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Subjects: | |
| Online Access: | https://www.dovepress.com/abiraterone-acetate-for-early-stage-metastatic-prostate-cancer-patient-peer-reviewed-article-TCRM |
| _version_ | 1818953814252716032 |
|---|---|
| author | Castellan P Marchioni M Castellucci R De Francesco P Iantorno R Schips L Cindolo L |
| author_facet | Castellan P Marchioni M Castellucci R De Francesco P Iantorno R Schips L Cindolo L |
| author_sort | Castellan P |
| collection | DOAJ |
| description | Pietro Castellan,1 Michele Marchioni,2 Roberto Castellucci,1 Piergustavo De Francesco,2 Romina Iantorno,1 Luigi Schips,1,2 Luca Cindolo1 1Department of Urology, ASL02 Abruzzo, Chieti, Italy; 2Department of Urology, University “G. d’Annunzio”, Chieti, Italy Abstract: In recent years, therapeutic advances, together with new medication sequences and combinations, have improved outcomes for prostate cancer. For a long time, androgen deprivation therapy (ADT) has been the standard of care for newly diagnosed, metastatic prostate cancer, first as a standalone therapy and then in combination with taxane-based regimens. More recently, the addition of abiraterone acetate to ADT to achieve complete androgen blockade has proven beneficial for the treatment of metastatic hormone-resistant prostate cancer and metastatic hormone-sensitive prostate cancer (mHSPC). In this review, we summarize recent findings on the early use of abiraterone in mHSPC and discuss survival benefits as reported in clinical trials. On the basis of existing data, abiraterone in combination with ADT could be considered a new standard of care for patients affected by mHSPC. Keywords: prostate cancer, metastatic hormone-sensitive prostate cancer, androgen receptor, hormonal therapy, abiraterone acetate, prostate castration naïve |
| first_indexed | 2024-12-20T10:12:02Z |
| format | Article |
| id | doaj.art-612d2fe350174f6095321a718c6182d7 |
| institution | Directory Open Access Journal |
| issn | 1178-203X |
| language | English |
| last_indexed | 2024-12-20T10:12:02Z |
| publishDate | 2018-12-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Therapeutics and Clinical Risk Management |
| spelling | doaj.art-612d2fe350174f6095321a718c6182d72022-12-21T19:44:07ZengDove Medical PressTherapeutics and Clinical Risk Management1178-203X2018-12-01Volume 142341234742856Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerationsCastellan PMarchioni MCastellucci RDe Francesco PIantorno RSchips LCindolo LPietro Castellan,1 Michele Marchioni,2 Roberto Castellucci,1 Piergustavo De Francesco,2 Romina Iantorno,1 Luigi Schips,1,2 Luca Cindolo1 1Department of Urology, ASL02 Abruzzo, Chieti, Italy; 2Department of Urology, University “G. d’Annunzio”, Chieti, Italy Abstract: In recent years, therapeutic advances, together with new medication sequences and combinations, have improved outcomes for prostate cancer. For a long time, androgen deprivation therapy (ADT) has been the standard of care for newly diagnosed, metastatic prostate cancer, first as a standalone therapy and then in combination with taxane-based regimens. More recently, the addition of abiraterone acetate to ADT to achieve complete androgen blockade has proven beneficial for the treatment of metastatic hormone-resistant prostate cancer and metastatic hormone-sensitive prostate cancer (mHSPC). In this review, we summarize recent findings on the early use of abiraterone in mHSPC and discuss survival benefits as reported in clinical trials. On the basis of existing data, abiraterone in combination with ADT could be considered a new standard of care for patients affected by mHSPC. Keywords: prostate cancer, metastatic hormone-sensitive prostate cancer, androgen receptor, hormonal therapy, abiraterone acetate, prostate castration naïvehttps://www.dovepress.com/abiraterone-acetate-for-early-stage-metastatic-prostate-cancer-patient-peer-reviewed-article-TCRMprostate cancermetastatic hormone-sensitive prostate cancerandrogen receptorhormonal therapyabiraterone acetateprostate castration naïve. |
| spellingShingle | Castellan P Marchioni M Castellucci R De Francesco P Iantorno R Schips L Cindolo L Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations Therapeutics and Clinical Risk Management prostate cancer metastatic hormone-sensitive prostate cancer androgen receptor hormonal therapy abiraterone acetate prostate castration naïve. |
| title | Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations |
| title_full | Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations |
| title_fullStr | Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations |
| title_full_unstemmed | Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations |
| title_short | Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations |
| title_sort | abiraterone acetate for early stage metastatic prostate cancer patient selection and special considerations |
| topic | prostate cancer metastatic hormone-sensitive prostate cancer androgen receptor hormonal therapy abiraterone acetate prostate castration naïve. |
| url | https://www.dovepress.com/abiraterone-acetate-for-early-stage-metastatic-prostate-cancer-patient-peer-reviewed-article-TCRM |
| work_keys_str_mv | AT castellanp abirateroneacetateforearlystagemetastaticprostatecancerpatientselectionandspecialconsiderations AT marchionim abirateroneacetateforearlystagemetastaticprostatecancerpatientselectionandspecialconsiderations AT castelluccir abirateroneacetateforearlystagemetastaticprostatecancerpatientselectionandspecialconsiderations AT defrancescop abirateroneacetateforearlystagemetastaticprostatecancerpatientselectionandspecialconsiderations AT iantornor abirateroneacetateforearlystagemetastaticprostatecancerpatientselectionandspecialconsiderations AT schipsl abirateroneacetateforearlystagemetastaticprostatecancerpatientselectionandspecialconsiderations AT cindolol abirateroneacetateforearlystagemetastaticprostatecancerpatientselectionandspecialconsiderations |